Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD47

CD47

Brief Information

Name:Cluster of differentiation 47
Target Synonym:MER6,CD47,Leukocyte surface antigen CD47,CD47 Molecule,Antigenic Surface Determinant Protein OA3,CD47 Antigen (Rh-Related Antigen, Integrin-Associated Signal Transducer),Antigen Identified By Monoclonal Antibody 1D8,Integrin Associated Protein,Rh-Related Antigen,CD47 Glycoprotein,IAP,Integrin-Associated Signal Transducer,Protein MER6,OA3,CD47 Antigen,Integrin-Associated Protein
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:36
Lastest Research Phase:Phase 3 Clinical

Licensing

Project item Indications Research phase Cooperation demands
BDA202202 Hematologic tumors, solid tumors License-out or co-development License-out or co-development

Product ListCompare or Buy

Cat. No. Species Product Description Structure Purity Feature
MBS-K023 Human Human CD47-coupled Magnetic Beads
CD7-H82A3 Human Biotinylated Human CD47 Protein, Mouse IgG2a Fc,Avitag™ (MALS verified)
CD7-H82A3-structure
CD7-H82A3-sds
CD7-HF2H3 Human FITC-Labeled Human CD47 Protein, His Tag
CD7-HF2H3-structure
CD7-HF2H3-sds
CD7-H82F8 Human Biotinylated Human CD47 Protein, Fc (L234A, L235A, P329G),Avitag™
CD7-H82F8-structure
CD7-H82F8-sds
CD7-M82E4 Mouse Biotinylated Mouse CD47 Protein, His,Avitag™
CD7-M82E4-structure
CD7-M82E4-sds
CD7-C52H5 Canine Canine CD47 Protein, His Tag
CD7-C52H5-structure
CD7-C52H5-sds
EP-102 Human CD47: SIRP alpha [Biotinylated] Inhibitor Screening ELISA Assay Pair
CD7-H522a Human Human CD47 Protein, His Tag, low endotoxin
CD7-H522a-structure
CD7-H522a-sds
CD7-H5251 Human Human CD47 Protein, Llama IgG2b Fc Tag, low endotoxin
CD7-H5251-structure
CD7-H5251-sds
CD7-M525a Mouse Mouse CD47 Protein, Mouse IgG2a Fc Tag, low endotoxin
CD7-M525a-structure
CD7-M525a-sds
CD7-M522b Mouse Mouse CD47 Protein, His Tag
CD7-M522b-structure
CD7-M522b-sds
CD7-C52H1 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque CD47 Protein, His Tag
CD7-C52H1-structure
CD7-C52H1-sds
CD7-HA2E9 Human Unconjugated Human CD47 Protein, His,Avitag™
CD7-HA2E9-structure
CD7-HA2E9-sds
CD7-H82E9 Human Biotinylated Human CD47 Protein, His,Avitag™
CD7-H82E9-structure
CD7-H82E9-sds
CD7-R5257 Rabbit Rabbit CD47 Protein, Fc Tag
CD7-R5257-structure
CD7-R5257-sds
CD7-R5256 Rat Rat CD47 Protein, Fc Tag
CD7-R5256-structure
CD7-R5256-sds
CD7-H52A5 Human Human CD47 Protein, Mouse IgG2a Fc Tag, low endotoxin
CD7-H52A5-structure
CD7-H52A5-sds
CD7-C5252 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque CD47 Protein, Fc Tag
CD7-C5252-structure
CD7-C5252-sds
CD7-M5251 Mouse Mouse CD47 Protein, Fc Tag
CD7-M5251-structure
CD7-M5251-sds
CD7-H82F6 Human Biotinylated Human CD47 Protein, Fc,Avitag™
CD7-H82F6-structure
CD7-H82F6-sds
CD7-H5227 Human Human CD47 Protein, His Tag (MALS verified)
CD7-H5227-structure
CD7-H5227-sds
CD7-H5256 Human Human CD47 Protein, Fc Tag (MALS verified)
CD7-H5256-structure
CD7-H5256-sds

Part of Bioactivity data

CD7-H82E9-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

FACS assay shows that Biotinylated Human CD47, His,Avitag (Cat. No. CD7-H82E9) can bind to ACHN cell expressing human SIRP-a. The concentration of CD47 used is 10 μg/mL (Routinely tested).

CD7-H82E9-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

FACS analysis shows that the binding of Human CD47 to ACHN expressing SIRP-a was inhibited by increasing concentration of neutralizing SIRP-a antibody. The concentration of Human CD47 used is 20 μg/mL. IC50=9.334 μg/mL

CD7-C52H1-SPR
Human_FcRn_Heterodimer_Protein_SPR

Anti-CD47 Mab (Human IgG4) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Cynomolgus/Rhesus macaque CD47, His Tag (Cat. No. CD7-C52H1) with an affinity constant of 1.8 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

CD7-H5227-SPR
Human_FcRn_Heterodimer_Protein_SPR

Anti-Human CD47 MAb (Human IgG4) captured on CM5 chip via Anti-Human IgG Fc antibodies surface, can bind Human CD47, His Tag (Cat. No. CD7-H5227) with an affinity constant of 1.66 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Customer Reviews

Synonym Name

CD47,MER6,IAP,OA3

Background

Leukocyte surface antigen CD47 is also known as Antigenic surface determinant protein OA3, Integrin-associated protein (IAP) and Protein MER6. CD47 contains 1 Ig-like V-type (immunoglobulin-like) domain. CD47 is very broadly distributed on normal adult tissues. CD47 has a role in both cell adhesion by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins and plays an important role in memory formation and synaptic plasticity in the hippocampus by similarity. CD47 is the receptor for SIRPA, binding to which prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. CD47 Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and costimulates T-cell activation.

Clinical and Translational Updates

Related Molecule

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Monoclonal Antibody (Mab) sB24M Phase 1 Clinical Pyoderma Gangrenosum Details
TTI-622 TTI-622 Phase 1 Clinical Trillium Therapeutics Inc Multiple Myeloma; Leukemia, Myeloid, Acute; Lymphoma Details
CC-90002 INBRX-103; CC-90002 Phase 1 Clinical Inhibrx Hematologic Neoplasms; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin Details
SG404 SG-404; SG404 Phase 1 Clinical Hangzhou Sumgen Biotechnology Co Ltd Neoplasms Details
IMM-2902 IMM-2902 Phase 1 Clinical ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd Solid tumours Details
IMM-0306 IMM-0306 Phase 1 Clinical ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd Lymphoma, B-Cell Details
TG-1801 NI-1701; TG-1801 Phase 1 Clinical Novimmune Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
AO-176 AO-176; Ti-104; Ti-108; Ti-176 Phase 2 Clinical Arch Oncology Solid tumours; Neoplasms; Multiple Myeloma Details
Anti-CD47 monoclonal antibody (Biocad) Phase 1 Clinical Biocad Neoplasms Details
CPO-107 Phase 2 Clinical Conjupro Biotherapeutics Inc Lymphoma, Non-Hodgkin Details
SG-2501 SG-2501 Phase 1 Clinical Hangzhou Sumgen Biotechnology Co Ltd Hematologic Neoplasms Details
STI-6643 STI-6643 Phase 1 Clinical Sorrento Therapeutics Inc Solid tumours Details
Letaplimab IBI-188 Phase 3 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours; Myelodysplastic Syndromes; Neoplasms; Myeloproliferative Disorders; Adenocarcinoma of Lung; Osteosarcoma; Leukemia, Myeloid, Acute Details
SG12473 SG12473; SG-12473 Phase 1 Clinical Hangzhou Sumgen Biotechnology Co Ltd Hematologic Neoplasms; Solid tumours Details
PF-07257876 Phase 1 Clinical Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung Details
IMM2505 IMM2505 Phase 1 Clinical Shenghe (China) Biopharmaceutical Co Ltd Solid tumours Details
SL-172154 SL-172154 Phase 1 Clinical Shattuck Labs Inc Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Peritoneal Neoplasms; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms Details
RRx-001 ABDNAZ; RRx-001 Phase 3 Clinical Epicentre Biotechnologies Llc Solid tumours; Glioblastoma; Carcinoma, Ovarian Epithelial; Small Cell Lung Carcinoma; Central Nervous System Neoplasms; Oligodendroglioma; Neuroendocrine Tumors; Brain Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Lymphoma; Carcinoma, Small Cell; Brain metastases; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Stomatitis Details
ZL-1201 ZL-1201 Phase 1 Clinical Zai Lab (Shanghai) Co Ltd Solid tumours; Hematologic Neoplasms Details
Ontorpacept TTI-621 Phase 2 Clinical The Hospital For Sick Children, University Health Network Leukemia, Promyelocytic, Acute; Solid tumours; Hematologic Neoplasms; Leiomyosarcoma; Papillomavirus Infections; Sarcoma; Breast Neoplasms; Carcinoma, Squamous Cell; Mycosis Fungoides; Melanoma Details
IMC-002 IMC-002; 3D-197; 3D197 Phase 1 Clinical Immuneoncia Therapeutics Solid tumours; Neoplasms; Lymphoma Details
HX-009 HX-009 Phase 2 Clinical Hangzhou Hansi Biomedicine Co Ltd, Wuhan Hanxiong Biotechnology Co Ltd Liver Neoplasms; Hematologic Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Lymphoma; Carcinoma, Non-Small-Cell Lung; Melanoma Details
SHS-009 SHS-009; SH009; SH-009 Phase 1 Clinical Nanjing Sanhome Pharmaceutical Co Ltd Neoplasms Details
Urabrelimab SRF-231 Phase 1 Clinical Surface Oncology Solid tumours; Hematologic Neoplasms Details
IMM 01(ImmuneOnco Biopharma) IMM01; IMM 01 Phase 2 Clinical ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd Leukemia, Promyelocytic, Acute; Myelodysplastic Syndromes; Hodgkin Disease; Multiple Myeloma; Lymphoma, Extranodal NK-T-Cell; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin Details
Simridarlimab IBI-322 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours; Hematologic Neoplasms; Bone Marrow Neoplasms; Neoplasms; Leukemia, Myeloid, Acute Details
6MW-3211 6MW3211; 6MW-3211 Phase 2 Clinical Mabwell (Shanghai) Bioscience Co Ltd Neoplasms Details
TQB2928 Phase 1 Clinical Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd Hematologic Neoplasms; Solid tumours; Neoplasms Details
BAT-7104 BAT-7104 Phase 1 Clinical Bio-Thera Solutions Ltd Solid tumours; Neoplasms Details
Kintuzumab(GenSci) Phase 1 Clinical Changchun Genescience Pharmaceutical Co Ltd Solid tumours; Hematologic Neoplasms; Lymphoma, Non-Hodgkin; Lymphoma Details
AL-008 AL-008; IBI-397 Phase 1 Clinical Alector Neoplasms Details
Magrolimab 5-F-9; Hu5F9-G4; ONO-7913 Phase 3 Clinical Stanford University Hematologic Neoplasms; Ovarian Neoplasms; Solid tumours; Leukemia, Myeloid; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Myelodysplastic Syndromes; Carcinoma, Transitional Cell; Multiple Myeloma; Urinary Bladder Neoplasms; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin Details
Evorpacept ALX148; ALX-148 Phase 3 Clinical Alexo Therapeutics Head and Neck Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Myelodysplastic Syndromes; Colorectal Neoplasms; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Neoplasm Metastasis; Adenocarcinoma Details
DSP-107 DSP-107; KAHR-107 Phase 2 Clinical Kahr Medical Solid tumours; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung Details
Ligufalimab AK-117 Phase 2 Clinical Zhongshan Akeso Biopharma Co Ltd Solid tumours; Squamous Cell Carcinoma of Head and Neck; Myelodysplastic Syndromes; Neoplasms; Triple Negative Breast Neoplasms; Leukemia, Myeloid, Acute; Lymphoma Details
Lemzoparlimab TJ-011133; TJC-4; ABBV-IMAB-TJC4; TJ-1133 Phase 2 Clinical I-Mab Biopharma Co Ltd, Abbvie Inc Solid tumours; Myelodysplastic Syndromes; Multiple Myeloma; Leukemia, Myeloid, Acute; Lymphoma Details
JMT-601 JMT-601 Phase 1 Clinical Shanghai Jinmante Biological Technology Co Ltd Lymphoma, Non-Hodgkin Details
Recombinant humanized monoclonal antibody MIL95(Mabworks/Connaught Biomedical Technology) MIL-95; CM-312 Phase 1 Clinical Beijing Mabworks Biotech Co Ltd, Keymed Biosciences Co Ltd Solid tumours; Lymphoma; Leukemia, Myeloid, Acute Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message